保肝降酶治疗对慢性乙型肝炎患者IL-17和ANA的影响  

Effects of compound glycyrrhizin preparation on IL-17 and ANA in patients with chronic hepatitis B

作　　者：殷杰[1] 冯灏[1] 陈速[1] 杨莉[1] 

机构地区：[1]东南大学附属南京江北人民医院感染病科,江苏省210048

出　　处：《江苏医药》2013年第11期1280-1281,共2页Jiangsu Medical Journal

基　　金：南京市医学科技发展项目(YKK11197)

摘　　要：目的探讨保肝降酶治疗对慢性乙型肝炎(慢乙肝)患者血清IL-17和抗核抗体(ANA)水平的影响。方法对30例慢乙肝患者(慢肝组)给予复方甘草酸苷制剂治疗3周,随机抽取乙肝病毒携带者30例为对照组,检测血清IL-17和ANA表达。结果慢肝组患者使用复方甘草酸苷制剂治疗前后IL-17和ANA表达均无明显差异[(182.546±17.731)pg/ml vs.(177.201±16.247)pg/ml和0.867±0.446vs.0.645±0.285](P>0.05);但ANA表达均明显高于对照组的0.555±0.281(P<0.01和P<0.05)。结论仅使用保肝降酶治疗,不能有效降低血清IL-17及ANA水平。Objective To investigate the effects of compound glycyrrhizin preparation on IL-17 and antineuclear antibody（ANA） in the patients with chronic hepatitis B（CHB）. Methods Thirty patients with CHB（group A） were treated with compound glycyrrhizin preparation for three weeks. The expressions of IL-17 and ANA were detected in CHB eases before and after treatment and in 30 cases carrying hepatitis B virus（group B）. Results The expressions of IL-17 in group A were not significantly changed before and after treatment[（182. 546± 17. 731） pg/ml vs. （177. 201 ± 16. 247） pg/ml]（P〈0. 05）. So did that of ANA（0. 867±0. 446 vs. 0. 645±0. 285）（P〈0. 05） ,but which were higher than 0. 555±0. 281 in group B（P〈0. 01 and P〈0. 05）. Conclusion The treatment of CHB with compound glycyrrhizin preparation can not significantly reduce the expressions of IL-17 and ANA in the patients with CHB.

关 键 词：慢性乙型肝炎 白细胞介素17 抗核抗体 

分 类 号：R512[医药卫生—内科学]